Sodium Sulfacetamide

Manufacturer
E. FOUGERA & Co., A division of Nycomed US Inc. | Nycomed US Inc.
Effective date
2010-03-12
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:09:08

Label at a glance#

ProductSodium Sulfacetamide
Active ingredientsulfacetamide sodium
Label structure13 sections

Indications and uses

Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

Dosage and administration

Gently apply Sodium Sulfacetamide Medicated Pads to the affected areas 1 to 2 times daily or as directed by a physician until the infection has cleared.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

in a Urea Vehicle

FOR DERMATOLOGIC USE ONLY

Rx only

NOT FOR OPHTHALMIC USE

DESCRIPTION:

DESCRIPTION SECTION

Sodium Sulfacetamide Medicated Pads 10% contain a 10% solution of sodium sulfacetamide on a textured pad. Each gram of medicated solution contains 100 mg sodium sulfacetamide, purified water, sodium EDTA, sodium thiosulfate and urea ( 1 0%). Sodium Sulfacetamide Medicated Pads are greaseless and leave no residue when applied to the skin.

Sodium sulfacetamide is a sulfonamide with antibacterial activity. Chemically, sodium sulfacetamide is C8H9N2Na03S•H2O, with a molecular weight of 254.24. Chemically it is acetamide, N- [(4 aminophenyl) sulfonyl]-, monosodium salt and monohydrate, with the following structural formula:

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY:

CLINICAL PHARMACOLOGY SECTION

Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide-sensitive gram-positive and gram-negative micro-organism including P. acne commonly isolasted from secondary cutaneous pyogenic infections.

The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid P ( ABA), an essential component for bacterial growth. While absorption through intact skin in humans has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine largely unchanged. The biological half-life has variously been reported as 7 o t 12.8 hours.

INDICATIONS AND USAGE:

INDICATIONS & USAGE SECTION

Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Sodium Sulfacetamide Medicated Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the preparation. Sodium Sulfacetamide Medicated Pads are not to be used by patients with kidney disease.

WARNINGS:

WARNINGS SECTION

Although rare, sensitivity t o sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported.

PRECAUTIONS:

PRECAUTIONS SECTION

GENERAL PRECAUTIONS SECTION

General: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. Hypersensitivity reactions may recur when a sulfonamide is readministered, irrrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. If Sodium Sulfacetamide Medicated Pads produce signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded, or severely burned areas. Under these circumstances, potentially any of the adverse effects produced by the systemic administration of these agents could occur, and appropriate observations and laboratory determinations should be performed.

INFORMATION FOR PATIENTS:

INFORMATION FOR PATIENTS SECTION

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Patients should discontinue the use of Sodium Sulfacetamide Medicated Pads if the condition becomes worse, or if a rash develops in the area being treated or elsewhere. Sodium Sulfacetamide Medicated Pads also should be discontinued promptly and the physician notified if any arthritis, fever, or sores in the mouth develop.

DRUG INTERACTIONS SECTION

Drug Interactions: Sodium Sulfacetamide Medicated Pads are incompatible with silver preparations.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on Sodium Sulfacetamide Medicated Pads.

PREGNANCY SECTION

Pregnancy Category C: Animal reproduction studies have not been conducted with Sodium Sulfacetamide Medicated Pads. It also is not known whether Sodium Sulfacetamide Medicated Pads can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Sulfacetamide Medicated Pads should be used by a pregnant woman only if clearly needed.

NURSING MOTHERS SECTION

Nursing Mothers: It is not known whether this drug is excreted in human milk following topical use of Sodium Sulfacetamide Medicated Pads. Because many drugs are excreted in human milk, caution should be exercised when Sodium Sulfacetamide Medicated Pads are administered to a nursing woman.

PEDIATRIC USE SECTION

Pediatric Use: Safety and effectiveness in children below the age of 12 years have not been established.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity, which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome has been reported (see WARNINGS).

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Gently apply Sodium Sulfacetamide Medicated Pads to the affected areas 1 to 2 times daily or as directed by a physician until the infection has cleared.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Sodium Sulfacetamide Medicated Pads NDC 0168-0484-01 contain 30 Foil Pouches, each with a single-use medicated pad (2.5 mL each).

Store at 15°-30° C (59°-86° F). Protect from freezing.

Sodium Sulfacetamide Medicated Pads may darken after prolonged storage. Slight discoloration does not impair the efficacy or safety of the product.

Manufactured for: E. FOUGERA & CO.
A division of Nycomed US Inc., Melville New York 11747
Manufactured by: Pegasus Laboratories, Inc., Pensacola, FL 32514

IL302A R3/09

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CARTON – 30 CT

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0484-01

30 Foil Pouches (2.5 mL each)

Fougera®

SODIUM SULFACETAMIDE

Medicated Pads 10%

In a Urea Vehicle

For Topical Use Only

For dermatologic use only – not for ophthalmic use

Contains: 30 Foil Pouches, each with a single-use medicated pad (2.5 mL each)

Rx only

E. FOUGERA & CO.

A division of Nycomed US Inc.

Melville, New York 11747

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CARTON – 30 CT
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CARTON – 30 CT

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CONTAINER – 2.5 mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0168-0484-01

2.5 mL

Fougera®

SODIUM SULFACETAMIDE

Medicated Pads 10%

in a Urea Vehicle

For Topical Use Only

For dermatologic use only – not for ophthalmic use

Single-use medicated pad 2.5 mL

Rx only

E. FOUGERA & CO.

A division of Nycomed US Inc.

Melville, New York 11747

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CONTAINER – 2.5 mL
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – CONTAINER – 2.5 mL

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
SULFACETAMIDE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
4073022c-5d5d-48f5-82ed-091ad146a4b2Product name120171211
9ffbd0ae-0bce-c086-b707-f0da5f8cd7c5Product name120150828
0304b7d2-7a07-d53b-750f-36012ae6612eProduct name120140508
64c0cc7e-6478-3ca1-8cd7-9a1251d5a3f6Product name120140508
9ae74339-0a3d-82e9-5dd1-88bd2607bd6bProduct name120140508
e44e38a9-2d9e-b0e2-cce9-490554639f3dProduct name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
0168-0484-012019-10-21C16284748780-1956f9ecf-d6ce-621f-e053-dbdaa90a74adSODIUM SULFACETAMIDE Medicated Pads 10%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0168-0484-01Sodium Sulfacetamide30 in 1 CARTONSOLUTION301
0168-0484-01Sodium Sulfacetamide1 in 1 POUCHSOLUTION11

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0168-0484SODIUM SULFACETAMIDE SOLUTION [E. FOUGERA & CO., A DIVISION OF NYCOMED US INC.]1Legacy NDC, 2 package rows20100719_5fe3a841-260d-4844-8169-c613a27408fd.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
sulfacetamide sodiumACTIVE INGREDIENT4NRT660KJQ1
sulfacetamideACTIVE MOIETY4965G3J0F51
sodium thiosulfateINACTIVE INGREDIENTHX1032V43M1
ureaINACTIVE INGREDIENT8W8T17847W1
waterINACTIVE INGREDIENT059QF0KO0R1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0168-04840168-0484-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 17 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ureaUREA8W8T17847WCREAM / VAGINAL0.64 %w/wExact identifier — unii candidate
7 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MCAPSULE / ORAL20 mgExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MTABLET / ORAL3 mgExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSOLUTION/ DROPS / ORAL0.5 mg/1mlExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MINJECTION / INTRAVENOUS18 mgExact identifier — unii candidate
10 equally ranked IID candidates
ureaUREA8W8T17847WDOUCHE / VAGINAL8 %w/wExact identifier — unii candidate
7 equally ranked IID candidates
ureaUREA8W8T17847WTABLET, EFFERVESCENT / ORAL60 mgExact identifier — unii candidate
7 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MCREAM / TOPICAL6 mgExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSOLUTION/ DROPS / OPHTHALMIC0.31 %w/vExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSOLUTION / OPHTHALMIC0.5 %w/vExact identifier — unii candidate
10 equally ranked IID candidates
ureaUREA8W8T17847WTABLET, COATED / ORAL0.02 mgExact identifier — unii candidate
7 equally ranked IID candidates
ureaUREA8W8T17847WSYSTEM / TOPICAL840 mgExact identifier — unii candidate
7 equally ranked IID candidates
ureaUREA8W8T17847WTABLET, EXTENDED RELEASE / ORAL0.01 mgExact identifier — unii candidate
7 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSOLUTION / ORAL22 mg/1mlExact identifier — unii candidate
10 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSUSPENSION / OPHTHALMIC0.32 %w/wExact identifier — unii candidate
10 equally ranked IID candidates
ureaUREA8W8T17847WINSERT / VAGINAL50 mgExact identifier — unii candidate
7 equally ranked IID candidates
sodium thiosulfateSODIUM THIOSULFATEHX1032V43MSUSPENSION/ DROPS / OPHTHALMIC3.15 %w/wExact identifier — unii candidate
10 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
cc939c60-abf2-40dd-af3c-87281e9fc1ca5fe3a841-260d-4844-8169-c613a27408fd2010-03-12Warnings, Adverse reactionsExact identifier
spl id: cc939c60-abf2-40dd-af3c-87281e9fc1ca
spl set id: 5fe3a841-260d-4844-8169-c613a27408fd

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.